Tempest Therapeutics, Inc. (NASDAQ:TPST – Free Report) – Equities research analysts at HC Wainwright raised their Q3 2026 earnings per share estimates for Tempest Therapeutics in a research report issued on Thursday, September 24th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($0.32) per share for the quarter, up from their prior forecast of ($0.35). The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($0.83) per share. HC Wainwright also issued estimates for Tempest Therapeutics’ Q4 2026 earnings at ($0.29) EPS, FY2026 earnings at ($0.83) EPS and FY2027 earnings at ($0.90) EPS.
Tempest Therapeutics (NASDAQ:TPST – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.04).
Get Our Latest Stock Report on Tempest Therapeutics
Tempest Therapeutics Stock Down 2.6%
Shares of NASDAQ TPST opened at $0.81 on Monday. The company has a market cap of $13.40 million, a PE ratio of -0.19 and a beta of -1.68. The firm’s 50-day moving average price is $0.97 and its 200-day moving average price is $1.37. Tempest Therapeutics has a 52-week low of $0.74 and a 52-week high of $12.23.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Tempest Therapeutics stock. Squarepoint Ops LLC acquired a new position in Tempest Therapeutics, Inc. (NASDAQ:TPST – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 30,900 shares of the company’s stock, valued at approximately $34,000. Squarepoint Ops LLC owned about 0.19% of Tempest Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 22.52% of the company’s stock.
About Tempest Therapeutics
Tempest Therapeutics, Inc is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. Its research combines tumor-targeted approaches with immune-system modulation, with the goal of addressing both cancer-cell biology and the tumor microenvironment.
The company’s pipeline has included TPST-1120, an oral, selective antagonist of peroxisome proliferator-activated receptor alpha (PPARĪ±). The program is being investigated for advanced solid tumors, including hepatocellular carcinoma, as a monotherapy and in combination with other cancer treatments.
Recommended Stories
- Five stocks we like better than Tempest Therapeutics
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
- Bottlenecking the Future: TSMC Prices Out the Competition
- Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock?
Receive News & Ratings for Tempest Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempest Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
